Skip to main content

Five Steps to a Potential COVID-19 Treatment

Learn the process – now underway – to develop a “hyperimmune” derived from plasma.


This summer, an alliance of the world’s top plasma medicine companies expects to launch a clinical trial of a potential treatment for COVID-19. The unbranded “hyperimmune” aims to deliver a reliable dose of antibodies in a refined treatment that could be produced at scale and then stocked by hospitals. Learn more about how the process will work: 

5 steps to developing a potential hyperimmune treatment
Donations of convalescent plasma are critical to the success of the effort. To learn more about donating, visit